Publication | Open Access

Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer

Medicinal ChemistrySelective 17,20-Lyase InhibitorPotential UtilityMedicinePharmacotherapyAnti-cancer AgentProstatic DiseaseDrug DevelopmentPharmacologyRadiation OncologyPharmaceutical ChemistryDrug Discovery